Perspective Therapeutics (NYSE:CATX) Trading Down 5.9%

Perspective Therapeutics, Inc. (NYSE:CATX) traded down 5.9% during trading on Monday . The company traded as low as $12.35 and last traded at $12.45. 237,227 shares were traded during mid-day trading, a decline of 64% from the average session volume of 652,009 shares. The stock had previously closed at $13.23.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. Oppenheimer lowered their price target on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Bank of America initiated coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price target for the company. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $19.80.

Perspective Therapeutics Price Performance

The business has a fifty day moving average price of $13.81.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. On average, analysts anticipate that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new position in Perspective Therapeutics in the 2nd quarter worth about $117,000. Point72 DIFC Ltd bought a new position in Perspective Therapeutics in the 2nd quarter worth about $118,000. The Manufacturers Life Insurance Company bought a new position in Perspective Therapeutics in the 2nd quarter worth about $188,000. ZWJ Investment Counsel Inc. bought a new position in Perspective Therapeutics in the 1st quarter worth about $26,000. Finally, Bleakley Financial Group LLC bought a new position in Perspective Therapeutics in the 1st quarter worth about $40,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.